The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

The capture efficiency of BioMagnetic solutions FerroSelect in PBS/1% BSA and whole blood showed a decrease in capture efficiency when moving to whole blood. by Peng Liu (120506)

“…<p>The capture efficiency of BioMagnetic solutions FerroSelect in PBS/1% BSA and whole blood showed a decrease in capture efficiency when moving to whole blood.…”

Decreased virulence observed during <i>in planta</i> infection with <i>ΔFgknr4</i>. by Erika Kroll (20537020)

“…In wheat inoculated with <i>ΔFgknr4</i> compared to WT, decreased host colonisation is observed, evidenced by (i) reduced fungal hyphae proliferation, particularly in the thicker adaxial cell layer, (ii) collapsed air spaces in wheat cells, and (iii) increased polymer deposition at the wheat cell walls (black arrows), indicating an enhanced defence response. …”

Data Sheet 1_Decreased cigarette smoking may partially explain the increased prevalence of antinuclear antibodies in the United States.pdf by Gregg E. Dinse (4500940)

“…</p>Discussion<p>Although smoking causes harmful health effects, ANA data are consistent with smoking playing a role in decreasing autoimmunity. Recent vaping among adolescents may partially explain their large increase in ANA prevalence. …”

Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. by Erika Kroll (20537020)

Pan-neuronal <i>dMaf1</i> knockdown decreases <i>dMaf1</i> mRNA level in brains and consistently extends lifespan. by Bowen Xu (5903801)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Astrocytes increase contact with vessels and expression of AQP4 following Mtb infection, which is decreased in cytosis⁺ animals. by Amanda S. Latham (12093638)

“…Decreased expression of AQP4, and endfoot contact, is found in cytosis⁺ animals in the frontal cortex (D and E), cerebral nuclei (J and K), brain stem (P and Q), thalamus (V and W) and hippocampus (BB and CC). …”

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects: